Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 57,225 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 57,225 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $0.87, for a total value of $49,785.75. Following the transaction, the insider owned 4,867,341 shares in the company, valued at approximately $4,234,586.67. This trade represents a 1.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Thursday, December 4th, Bioventures 2014 L.P. Mpm sold 83,230 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $80,733.10.
• On Tuesday, December 2nd, Bioventures 2014 L.P. Mpm sold 59,277 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $52,756.53.
• On Monday, December 1st, Bioventures 2014 L.P. Mpm sold 60,917 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $57,261.98.
• On Friday, November 28th, Bioventures 2014 L.P. Mpm sold 20,277 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total value of $20,074.23.
• On Wednesday, November 26th, Bioventures 2014 L.P. Mpm sold 60,733 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $59,518.34.
• On Tuesday, November 25th, Bioventures 2014 L.P. Mpm sold 42,533 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.92, for a total transaction of $39,130.36.
• On Monday, November 24th, Bioventures 2014 L.P. Mpm sold 88,802 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $87,025.96.
• On Friday, November 21st, Bioventures 2014 L.P. Mpm sold 64,331 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total value of $53,394.73.
• On Thursday, November 20th, Bioventures 2014 L.P. Mpm sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $36,625.28.
• On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $62,344.56.

Werewolf Therapeutics Stock Up 8.5%

Shares of NASDAQ:HOWL traded up $0.08 during midday trading on Thursday, reaching $1.00. The company had a trading volume of 587,802 shares, compared to its average volume of 504,491. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38. The stock has a market cap of $48.36 million, a PE ratio of -0.61 and a beta of 0.74. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The business’s 50 day moving average price is $1.42 and its 200 day moving average price is $1.33.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. Research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HOWL has been the topic of a number of research reports. Bank of America decreased their price target on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. JMP Securities dropped their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Finally, Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HOWL. Quadrature Capital Ltd bought a new position in Werewolf Therapeutics in the 2nd quarter valued at approximately $28,000. Qube Research & Technologies Ltd acquired a new position in shares of Werewolf Therapeutics during the second quarter worth $48,000. Nuveen LLC bought a new stake in Werewolf Therapeutics during the 1st quarter worth $71,000. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics in the 1st quarter worth about $79,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Werewolf Therapeutics in the second quarter valued at about $92,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.